SCHEMBL3673183

SCHEMBL3673183

CCCC[Sn](CCCC)(CCCC)c1nnn(Cc2ccc(C(F)(F)F)cc2)c1-c1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.48
NR1H2 P55055 3/20 0.41
NR1H3 Q13133 3/20 0.41
GRM2 Q14416 3/20 0.40
PTGER4 P35408 1/20 0.40
RIPK3 Q9Y572 1/20 0.39
KCNK3 O14649 1/20 0.38
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
MET P08581 1/20 0.35
DAPK3 O43293 1/20 0.35
ROCK2 O75116 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
PIM1 P11309 1/20 0.35
PRKACA P17612 1/20 0.35
CDK2 P24941 1/20 0.35
FLT3 P36888 1/20 0.35
SYK P43405 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295553 0.87 CDC7 (0.46) CDC7GRM2IDO1TDO2DAPK3
SCHEMBL4706975 0.82 HSP90AA1 (0.35) CDC7GRM2RIPK3MAPK14
SCHEMBL4638838 0.81 POLB (0.38) NR1H2NR1H3GRM2PTGER4
SCHEMBL3670826 0.80 CDC7 (0.41) CDC7NR1H2NR1H3GRM2IDO1
SCHEMBL3669940 0.78 CYP19A1 (0.48) CDC7GRM2IDO1TDO2DAPK3
SCHEMBL4705960 0.76 HSP90AA1 (0.33)
SCHEMBL4759295 0.75 POLB (0.37)
SCHEMBL4295575 0.72 CDC7 (0.49) CDC7RIPK3MAPK14
SCHEMBL4708507 0.71 HSP90AA1 (0.34) GRM2
SCHEMBL4707683 0.71 HSP90AA1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885NR1H2 3233/4885NR1H3 2692/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885NR1H2 3233/4885NR1H3 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.